-
1Academic Journal
Authors: R. Ya. Mirgaliyeva, E. K. Khusnutdinova, R. I. Khusainova, Р. Я. Миргалиева, Э. К. Хуснутдинова, Р. И. Хусайнова
Source: Medical Genetics; Том 17, № 7 (2018); 3-10 ; Медицинская генетика; Том 17, № 7 (2018); 3-10 ; 2073-7998
Subject Terms: ПТГ, osteoporotic fractures, BMD, GWAS, RANK-RANKL-OPG, остеопоретические переломы, МПКТ
File Description: application/pdf
Relation: https://www.medgen-journal.ru/jour/article/view/527/343; NIH. Osteoporosis. National Institutes of Health Consensus Development Conference Statement. National Institutes of Health Consensus Development Conference Consensus Statement. 1984;5(3):1-6.; Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12(1):24-35.; Dhanwal DK, Dennison EM., Harvey NC, et. a l. Epidemiology of hip fracture: worldwide geographic variation. Indian J Orthop. 2011;45(1);15-22.; Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch intern Med. 1991 Oct;151(10);2026-2032.; Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Jun;97(6):1802-1822.; Ralston SH, UitterlinDen AG. Genetics of osteoporosis. Endocr Rev. 2010 Oct;31(5):629-662.; Seeley DG, Browner WS, Nevitt MC. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures. Ann Intern Med. 1991 Dec 1;115(11):837-842.; Kanis JA, Melton LJ, Christiansen C, et. a l. The Diagnosis of osteoporosis. J Bone Min Res. 1994 Aug;9(8):1137-1141.; Wright NC, Hooker ER, Nielson CM, et al.; Osteoporotic Fractures in Men (MrOS) Study Research Group. The epidemiology of wrist fractures in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int. 2018 Jan;17. doi:10.1007/s00198-017-4349-9; European Prospective Osteoporosis Study (EPOS) Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res. 2002;17:716-24.; Chang Y, Huang C, Hwang J, et al. Fracture liaison services for osteoporosis in the Asia-Pacific region: current unmet needs and systematic literature review. Osteoporos Int. 2017 Dec;28. doi:10.1007/s00198-017-4347-y.; Беневоленская Л.И., Лесняк О.М. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. Российская ассоциация по остеопорозу. М:Геотар-Медиа, 2005:171.; Беневоленская, Л.И. Руководство по остеопорозу. М5.: Бином, 2003:524.; Stewart A, Walker LG, Porter RW, et al. Prediction of a second hip fracture. J Clin Densitometry. 1999;2(4):363-70.; O Neill TW, Felsenberg D, Varlow J. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Min Res. 1996 Jul;11(7):1010-1018.; LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitmain D deficiency in postmenopausal US women with acute hip fracture. JAMA. 1999 Apr 28;282(16):1505-1511.; Rosen CJ. The Epidemiology and Pathogenesis of Osteoporosis. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. South Dartmouth (MA): MDText. com, Inc. 2000-2017 Feb 21:47.; Cushing H. The basophile adenomas of the pituitary body and their clinical manifestations (pituitary Basophilizm). Obes Res. 1994 Sep;2(5):486-508.; Tinetti ME, Speechely M, Gunter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988 Dec 29;319(26):1701-1707.; Miller PD. Guidelines for the clinical utilization of bone mass measurements in the adult population. Calcif Tiss Int.1995 Oct;57(4):252.; Luigi Gennari, John P. Bilezikian. Idiopatic Osteoporosis in Men, Curr Osteoporos Rep (2013) 11:286-298), äîñòèãàÿ ïèêîâîãî çíà÷åíèÿ ê 20 ãîäàì (Gilsanz V. Accumulation of bone mass during childhood and adolescence. In: Orwoll ES, ed. Osteoporosis in men. San Diego, Calif.: Academic, 1999:65-85; Gilsanz V, Loro ML, Roe TF, et al. Gender differences in vertebral size in adutls: biomechanical implications. J clin Invest. 1995 May;95(5):2332-2337.; Teegarden D, Proulx WR, Martin BR. Peak bone mass in young women. J Bone Miner Res. 1995 May;10(5):711-715.; Prior JC, Vigna Y, Schechter MT, Burgess AE. Spinal bone loss and ovulatory Disturbances. N Engl J Med. 1990 Nov 1;323(18):1221-1227.; Kiel DP, Demissie S, Dupuis J. Genome-wide association with bone mass and geometry in the Framingham Heart Study. BMC Med Genet. 2007 Sep 19;8Supp1:S14.; Altshuler D, Daly M., Land1er ES. Genetic mapping in human disease. Science. 2008 Nov 7;322(5903):881-888.; Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012 Apr 15;44(5):491-501.; Xiong DH, Liu XG, Guo YF, et al. Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groups. Am J Hum Genet. 2009 Mar;84(3):388-398.; Kung AWC, Xiao S-M, Cherny S, et al. Association of JAG1 with bone mineral density and osteoporotic fractures: a genome-wide association study and follow-up replication studies. American Journal of Human Genetics. 2010;86:229-239.; Hsu Y, Beck TJ, Brown SJ, et al. Meta-analysis of genome-wide association study (GWAS) identifies several genes for hip bone geometry in Caucasians: the Genetic Factors for Osteoporosis (GEFOS) Consortium. J Bone Miner Res. 2010a;25(Suppl 1):448.; Duncan EL, Danoy P, Kemp JP, et al. Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet. 2011 Apr;7(4):e1001372.; Tan LA, Liu R, Lei S, et al. A genome-wide association analysis implicates SOX6 as a candidate gene for wrist bone mass. Sci China Life Sci. 2010 Sep;53(8):1065-1072.; Cho YS, Go MJ, Kim YJ, et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet. 2009 May;41(5):527-534.; Paternoster L, Lorentzon M, Vandenput L, et al. Genome-wide association meta-analysis of cortical bone mineral density unravels allelic heterogeneity at the RANKL locus and potential pleiotropic effects on bone. PLoS Genet. 2010 Nov 18;6(11):e1001217.; Zhao LJ, Liu XG, Liu YZ, et al. Genome-wide association study for femoral neck bone geometry. J Bone Miner Res. 2010 Feb;25(2):320-329.; Guo Y, Zhang LS, Yang TL, et al. IL21R and ÏÒà may underlie variation of femoral neck bone mineral density as revealed by a genome-wide association study. J Bone Miner Res. 2010 May;25(5):1042-1048.; Albagha OM, Wani SE, Visconti MR, et al. Genome-wide association identifies three new susceptibility loci for Paget’s disease of bone. Nat Genet. 2011 May 29;43(7):685-689.; Medina-Gomez C, Kemp JP, Trajanoska K. Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects. Am J Hum Genet. 2018 Jan 4;102(1):88-102.; Xu XH, Dong SS, Guo Y, et al. Molecular genetic studies of gene identification for osteoporosis: the 2009 update. Endocr Rev. 2010 Aug;31(4):447-505.; Zhang, L, Choi HJ, Estrada K, et al. Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet. 2014 Apr 1;23(7):1923-33.; Liu, Y.J., Zhang, L., Papasian, C.J., Deng, H.W. Genome-wide association studies for osteoporosis: a 2013 update. J. Bone Metab.2014 May;21(2): 99-116.; Hwang JY, Lee SH, Go MJ, et al. Meta-analysis identifies a MECOM gene as a novel predisposing factor of osteoporotic fracture. J Med Genet 2013;50:212-219.; Wang Y, Li YP, Paulson C. et al. Wnt and the Wbt signaling pathway in bone development and disease. Front Biosci (Landmark Ed). 2014 Jan 1;19:379-407.; Mileyko Y, Joh RI, Weitz JS. Small-scale copy number variation and large-scale changes in gene expression. Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16659-64.; Deng FY, Zhao LJ, Pei YF, et al. Genome-wide copy number variation association study suggested VPS13B gene for osteoporosis in Caucasians. Osteoporos Int. 2010 Apr;21(4):579-87.; Chew S, Mullin BH, Lewis JR., et al. Homozygous deletion of the UGT2B17 gene is not associated with osteoporosis risk in elderly Caucasian women. Osteoporos Int. 2011 Jun;22(6):1981-6.; Michou L. Epigenetics of bone diseases. Joint Bone Spine. 2017 Dec 12. pii: S1297-319X(17)30208-7. doi:10.1016/j.jbspin.2017.12.003.; Valenti MT, Dalle Carbonare L, Mottes M. Role of microRNAs in progenitor cell commitment and osteogenic differentiation in health and disease (Review). Int J Mol Med. 2018 Feb 1.doi:10.3892/ijmm.2018.3452.; Delgado-Calle J, Garmilla P, Riancho JA. Do epigenetic marks govern bone mass and homeostasis?. Curr Genomics. 2012 May;13(3):252-63.; Delgado-Calle J, Sanudo C, Fernandez AF, et al. Role of DNA methylation in the regulation of the RANKL-OPG system in human bone. Epigenetics. 2012 Jan 1;7(1):83-91.; Santos FP, Kantarjian H, Garcia-Manero G, et al. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010 Jan;10(1):9-22.
-
2Academic Journal
Authors: N. V. Toroptsova, O. A. Nikitinskaya, O. V. Dobrovolskaya, Н. В. Торопцова, О. А. Никитинская, О. В. Добровольская
Source: Rheumatology Science and Practice; Vol 52, No 3 (2014); 336-341 ; Научно-практическая ревматология; Vol 52, No 3 (2014); 336-341 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20143
Subject Terms: приверженность лечению, остеопоретические переломы
File Description: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/1949/1221; Общая заболеваемость взрослого населения России в 2011 году. Статистические материалы. Москва: ФГБУ «Центральный научно-исследовательский институт организации и информатизации здравоохранения» МЗ РФ; 2012; Ч. 4: С.135–7. [Obshchaya zabolevaemost' vzroslogo nase- leniya Rossii v 2011 godu. Statisticheskie materialy. [The general incidence of adult population of Russia in 2011. Statistical materi- als.] Moscow: FGBU «Tsentral'nyi nauchno-issledovatel'skii insti- tut organizatsii i informatizatsii zdravookhraneniya» MZ RF; 2012; Pt 4: P.135–7.]; World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO, 2003.; Jennings LA, Auerbach AD, Maselli J, et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc. 2010;58(4):650–7. DOI: http://dx.doi.org/10.1111/j.1532-5415.2010.02769.x.; Shu AD-H, Stedman MR, Polinski JM, et al. Adherence to osteo- porosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care. 2009;15(7):417–24.; Rabenda V, Vanoverloop J, Fabri V, et al. Low incidence of anti- osteoporosis treatment after hip fracture. J Bone Joint Surg Am. 2008 Oct;90(10):2142–8. DOI: http://dx.doi.org/10.2106/JBJS.G.00864.; Curtis JR, Westfall AO, Cheng H, et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101.038 new bisphosphonate users. J Bone Miner Res. 2008;23(9):1435–41. DOI: http://dx.doi.org/10.1359/jbmr.080418.; Simonelli C, Chen YT, Morancey J, et al. Evaluation and manage- ment of osteoporosis following hospitalization for low-impact fracture. J Gen Intern Med. 2003 Jan;18(1):17–22. DOI: http://dx.doi.org/10.1046/j.1525-1497.2003.20387.x.; Schurink M, Hegeman JH, Kreeftenberg HG, Ten Duis HJ. Follow-up for osteoporosis in older patients three years after a fracture. Neth J Med. 2007;65(2):71–4.; Astrand J, Thorngren KG, Tagil M. One fracture is enough! Experience with a prospective and consecutive osteoporosis screening program with 239 fracture patients. Acta Orthop. 2006;77(1):3–8. DOI: http://dx.doi.org/10.1080/17453670610045623.; Follin SL, Black JN, McDermott MT. Lack of diagnosis and treat- ment of osteoporosis in men and women after hip fracture. Pharmacotherapy. 2003 Feb;23(2):190–8. DOI: http://dx.doi.org/10.1592/phco.23.2.190.32090.; Premaor MO, Pilbrow L, Tonkin C, et al. Low rates of treatment in postmenopausal women with a history of low trauma fractures: results of audit in a Fracture Liaison Service. QJM. 2010;103(1):33–40. DOI:10.1093/qjmed/hcp154. Epub 2009 Oct 28.; Roerholt C, Eiken P, Abrahamsen B. Initiation of anti-osteoporot- ic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int. 2009 Feb;20(2):299–307. DOI: http://dx.doi.org/10.1007/s00198-008- 0651-x.; Astrand J, Thorngren K-G, Tgil M, Еkesson K. 3-year follow-up of 215 fracture patients from a prospective and consecutive osteo- porosis screening program – Fracture patients care! Acta Orthop. 2008;79(3):404–9.; Kuo I, Ong C, Simmons L, et al. Successful direct intervention for osteoporosis in patients with minimal trauma fractures. Osteoporosis Int. 2007;18(12):1633–9. DOI: http://dx.doi.org/10.1007/s00198-007-0418-9.; Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteo- porosis prefer once weekly to once daily dosing with alendronate. Maturitas. 2004;48(3):243–51. DOI: http://dx.doi.org/10.1016/j.maturitas.2003.12.012.; Cramer J, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(9):1453–60. DOI: http://dx.doi.org/10.1185/030079905X61875.; Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005;21(12):1895–903. DOI: http://dx.doi.org/10.1185/030079905X74862.; Cooper A, Drake J, Brankin E; PERSIST investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60(8):896–905. DOI: http://dx.doi.org/10.1111/j.1742-1241.2006.01059.x. Epub 2006 Jun 19.; Hadji P, Felsenberg D, Amling M, et al. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int. 2014 Jan;25(1):339–47. DOI:10.1007/s00198-013-2515-2. Epub 2013 Oct 3.; Пядушкина ЕА, Герасимова КВ, Горяйнов СВ и др. Сравнительный фармакоэкономический анализ применения препарата Бонвива® (ибандронат) с целью профилактики переломов при постменопаузальном остеопорозе. Современная ревматология. 2012;(4):89–96. [Pyadushkina EA, Gerasimova KV, Goryainov SV, et al. Comparative pharmacoeco- nomic analysis of the use of Bonviva® (ibandronat) to prevent frac- tures in postmenopausal osteoporosis. Sovremennaya revmatologiya = Modern Rheumatology. 2012;(4):89–96. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2012-771.
-
3Academic Journal
Authors: N. V. Toroptsova, Н. В. Торопцова
Source: Rheumatology Science and Practice; Vol 52, No 4 (2014); 423-429 ; Научно-практическая ревматология; Vol 52, No 4 (2014); 423-429 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20144
Subject Terms: клинические рекомендации, osteoporotic fractures, bisphosphonates, FRAX algorithm, clinical guidelines, остеопоретические переломы, бисфосфонаты, алгоритм FRAX
File Description: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/1965/1235; Cushing H. The basophilic adenomas of the pituitary body and their clinical manifestations (pituitary asophilism). Bull Johns Hopkins Hosp. 1932;(1):137–92.; Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19(6):893–9. Epub 2004 Jan 27. DOI:http://dx.doi.org/10.1359/JBMR.040134.; Diez-Perez A, Hooven FH, Adachi JD, et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011;49(3):493–8. DOI:10.1016/j.bone.2011.05.007. Epub 2011 May 14.; Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39(2):253–9. Epub 2006 Mar 30. DOI: http://dx.doi.org/10.1016/j.bone.2006.02.005.; Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383–9. DOI: http://dx.doi.org/10.1093/rheumatology/39.12.1383.; Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004;15(4):323–8. DOI: http://dx.doi.org/10.1007/s00198-003- 1548-3. Epub 2004 Feb 5.; Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and ther predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003 Nov;48(11):3224–9. DOI: http://dx.doi.org/10.1002/art.11283.; Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoids-induced osteoporosis. Endocrinology. 1999;140(10):4382–9.; Gulko PS, Mulloy AL. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol. 1996;14(2):199–206.; Лесняк ОМ, Баранова ИА, Торопцова НВ. Клинические рекомендации: диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше. Ярославль: Литера; 2013. 48 с. [Lesnyak OM, Baranova IA, Toroptsova NV. Klinicheskie rekomendatsii: iagnostika, profilaktika i lechenie glyukokortikoidnogo osteoporoza u muzhchin i zhenshchin 18 let i starshe [Clinical recommendations: diagnostics, prevention and treatment of glucocorticoid osteoporosis at men and women of 18 years also is more senior]. Yaroslavl': Litera; 2013. 48 p.]; Kanis JA, Johansson H, Oden A, McCloskey E. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809–16. DOI:10.1007/s00198-010-1524-7. Epub 2011 Jan 13.; Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, lacebocontrolled extension trial. Arthritis Rheum. 2001;44(1):202–11. DOI: http://dx.doi.org/10.1002/1529-0131(200101)44:1%3C202::AID-ANR27%3E3.0.CO;2-W.; De Nijs RN, Jacobs JW, Lems WF, et al.; STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355(7):675–84. DOI: http://dx.doi.org/10.1056/NEJMoa053569.; Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroidinduced osteoporosis in men and women: a randomized trial. European Corticosteroid- Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000;15(6):1006–13. DOI: http://dx.doi.org/10.1359/jbmr.2000.15.6.1006.; Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67(4):277–85. DOI: http://dx.doi.org/10.1007/s002230001146.; Reid DM, Devogelaer JP, Saag K, et al.; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoidinduced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253–63. DOI:10.1016/S0140-6736(09)60250-6.; Saag KG, Shane E, Boonen S,et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–39. DOI: http://dx.doi.org/10.1056/NEJMoa071408.; Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, doubleblind, controlled trial. Arthritis Rheum. 2009;60(11):3346–55. DOI:10.1002/art.24879.; Compston J, Reid DM, Boisdron J, et al.; Group for the Respect of Ethics and Excellence in Science. Recommendations for the registration of agents for prevention and treatment of lucocorticoid- induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int. 2008;19(9):1247–50. DOI:10.1007/s00198-008-0670-7. Epub 2008 Jul 5.; De Nijs RN, Jacobs JW, Lems WF, et al.; Investigators STOP. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355(20):675–84. DOI: http://dx.doi.org/10.1056/NEJMoa053569.; De Nijs RN, Jacobs JW, Algra A, et al. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with metaanalysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004 Aug;15(8):589–602. DOI: http://dx.doi.org/10.1007/s00198-004-1614-5.; Roux C, Reid DM, Devogelaer JP, et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int. 2011;23(3):1083–90. DOI:10.1007/s00198-00011-01800-00191.; Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009;20(12):2095–104. DOI:10.1007/s00198-009-0917-y. Epub 2009 Apr 7.; Yeap SS, Fauzi AR, Kong NC, et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. J Rheumatol. 2008;35(12):2344–7. DOI:10.3899/jrheum.080634. Epub 2008 Nov 1.
-
4Academic Journal
Authors: Торопцова, Наталья
Subject Terms: ГЛЮКОКОРТИКОИДНЫЙ ОСТЕОПОРОЗ, ОСТЕОПОРЕТИЧЕСКИЕ ПЕРЕЛОМЫ, БИСФОСФОНАТЫ, АЛГОРИТМ FRAX, КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ
File Description: text/html
-
5Academic Journal
Authors: Торопцова, Наталья, Никитинская, О., Добровольская, О.
Subject Terms: ОСТЕОПОРОЗ, ОСТЕОПОРЕТИЧЕСКИЕ ПЕРЕЛОМЫ, ПРИВЕРЖЕННОСТЬ ЛЕЧЕНИЮ
File Description: text/html
-
6Academic Journal
Authors: Ильина, Р., Мухамеджанова, Л., Зиганшина, Л., Гурьянова, Т.
Subject Terms: ОСТЕОПОРОЗ,ОСТЕОПОРЕТИЧЕСКИЕ ПЕРЕЛОМЫ,ПСИХИЧЕСКИ БОЛЬНЫЕ,OSTEOPOROSIS,OSTEOPOROTIC FRACTURES,PSYCHIATRIC PATIENTS
File Description: text/html
-
7Academic Journal
Source: Научно-практическая ревматология.
Subject Terms: ГЛЮКОКОРТИКОИДНЫЙ ОСТЕОПОРОЗ, ОСТЕОПОРЕТИЧЕСКИЕ ПЕРЕЛОМЫ, БИСФОСФОНАТЫ, АЛГОРИТМ FRAX, КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ, 3. Good health
File Description: text/html
-
8Academic Journal
Source: Научно-практическая ревматология.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, ОСТЕОПОРОЗ, ОСТЕОПОРЕТИЧЕСКИЕ ПЕРЕЛОМЫ, ПРИВЕРЖЕННОСТЬ ЛЕЧЕНИЮ, 3. Good health
File Description: text/html
-
9Academic Journal
Source: Практическая медицина.
File Description: text/html
